Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · X4 Pharmaceuticals, Inc (XFOR)

X4 Pharmaceuticals posts updated corporate presentation with Phase 3 timeline

Neutral Impact 2 of 5 other Written later

X4 Pharmaceuticals posted an updated corporate presentation on its website on September 8, 2026, filed as Exhibit 99.1 to a Form 8-K. The filing reiterates the timeline for its pivotal Phase 3 4WARD study of mavorixafor in chronic neutropenia, with full enrollment expected in Q4 2026 and top-line data expected in H1 2028, and it reports cash of $208 million as of June 30, 2026.

Key points

  • Presentation dated September 8, 2026, posted to the Investors section of the company website
  • Full enrollment in the 4WARD Phase 3 study expected in Q4 2026; top-line data expected in H1 2028
  • Cash of $208 million and 145.6 million fully diluted shares outstanding as of June 30, 2026; cash runway expected into 2029

The filing

CompanyX4 Pharmaceuticals, Inc (XFOR)
Form8-K, current report
Filed with the SECSep 8, 2026, 5:36 PM ET
Accession number0001501697-26-000076

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 08, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.